Department of Interventional Cardiology, EMO-GVM Centro Cuore Columbus, Milan, Italy.
Catheter Cardiovasc Interv. 2013 Apr;81(5):810-7. doi: 10.1002/ccd.24600. Epub 2012 Nov 8.
This case series raises further awareness of the potential for longitudinal shortening with the Promus Element™ (Boston Scientific, MN) drug-eluting stent (DES) platform. With safety at the forefront of DES development, newer generation systems are utilizing thinner platforms with little or no polymer. Although these contemporary, ultrathin platforms also improve conformability and deliverability, specific design characteristics might inadvertently reduce longitudinal strength. To date, there are no randomized data addressing this issue in vivo for any stent platform, with opinion based on individual experience and bench testing. We report five cases of longitudinal shortening with the Promus Element stent occurring in our institution over a 15-month period. During the same period, we experienced only isolated cases with other second generation DES platforms. Our experience supports recently published bench-top data correlating the two-link design of this platform with the risk of compression.
本病例系列进一步提高了对 Promus Element™(波士顿科学公司,明尼苏达州)药物洗脱支架(DES)平台纵向缩短潜在风险的认识。在安全性处于 DES 开发的首要地位的情况下,新一代系统正在使用更薄的平台,其聚合物含量很少或没有。尽管这些现代的超薄平台也提高了顺应性和可输送性,但特定的设计特征可能会无意中降低纵向强度。迄今为止,尚无任何支架平台的体内随机数据可解决此问题,其观点基于个人经验和台架测试。我们报告了在我们的机构中在 15 个月的时间内发生的 5 例 Promus Element 支架的纵向缩短病例。在此期间,我们仅在其他第二代 DES 平台中遇到了孤立的病例。我们的经验支持了最近发表的台架数据,该数据将该平台的双链接设计与压缩风险相关联。